Quick Answer
PTC THERAPEUTICS, INC. reported Total Revenue of $1.73 billion for fiscal year 2025.
PTC THERAPEUTICS, INC. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $1.73B +114.5% |
$806.78M -14.0% |
$937.82M +34.2% |
$698.80M +29.7% |
$538.59M +41.4% |
$380.77M +24.0% |
| Revenue (ASC 606) | $1.73B +114.5% |
$806.78M -14.0% |
$937.82M +34.2% |
$698.80M +29.7% |
$538.59M +41.4% |
$380.77M +24.0% |
| Net Income | $682.64M +287.9% |
-$363.30M +42.0% |
-$626.60M -12.1% |
-$559.02M -6.7% |
-$523.90M -19.6% |
-$438.16M -74.2% |
| Diluted EPS | $7.78 +264.5% |
-$4.73 +43.5% |
-$8.37 -7.4% |
-$7.79 -4.8% |
-$7.43 -11.9% |
-$6.64 -55.5% |
| Total Assets | $2.90B +70.0% |
$1.71B -10.1% |
$1.90B +11.1% |
$1.71B -12.0% |
$1.94B -12.2% |
$2.21B +36.0% |
| Cash and Equivalents | $984.65M +26.3% |
$779.71M +31.3% |
$594.00M +112.3% |
$279.83M +47.5% |
$189.72M -9.1% |
$208.81M -27.5% |
| Long-Term Debt | — | $285.41M +0.4% |
$284.21M -50.3% |
$571.72M +102.8% |
$281.89M -8.8% |
$309.14M +5.2% |
| Stockholders Equity | -$205.31M +81.3% |
-$1.10B -34.1% |
-$818.55M -135.8% |
-$347.09M -24236.7% |
$1.44M -99.7% |
$481.98M -18.9% |
| R&D Expense | $455.25M -14.8% |
$534.48M -19.8% |
$666.56M +2.3% |
$651.50M +20.5% |
$540.68M +13.2% |
$477.64M +85.5% |
| Operating Income | $866.93M +386.5% |
-$302.57M +31.2% |
-$439.50M +1.8% |
-$447.41M -19.5% |
-$374.44M +13.3% |
-$431.77M -79.0% |
| Shares Outstanding | 81.47M +4.9% |
77.70M +2.6% |
75.71M +3.6% |
73.10M +3.2% |
70.83M +1.6% |
69.72M +12.6% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $211.01M | +7.2% | +18.0% |
| Revenue (ASC 606) | September 30, 2025 | $211.01M | +7.2% | +18.0% |
| Net Income | September 30, 2025 | $15.90M | +114.9% | +124.5% |
| Diluted EPS | September 30, 2025 | $0.20 | +114.4% | +124.1% |
| Total Assets | September 30, 2025 | $2.64B | +43.5% | +0.4% |
| Cash and Equivalents | September 30, 2025 | $672.62M | +27.9% | -33.9% |
| Long-Term Debt | June 30, 2025 | $286.01M | +0.4% | +0.1% |
| Stockholders Equity | September 30, 2025 | -$155.76M | +85.2% | +24.6% |
| R&D Expense | September 30, 2025 | $100.16M | -37.9% | -11.4% |
| Operating Income | September 30, 2025 | $3.02M | +105.5% | +108.6% |
| Shares Outstanding | September 30, 2025 | 79.93M | +3.9% | +0.7% |
- PTC THERAPEUTICS, INC. reported Total Revenue of $1.73 billion for fiscal year 2025.
- PTC THERAPEUTICS, INC. showed an increase of +114.5% in Total Revenue compared to the prior fiscal year.
- PTC THERAPEUTICS, INC. reported Revenue (ASC 606) of $1.73 billion for fiscal year 2025.
- PTC THERAPEUTICS, INC. showed an increase of +114.5% in Revenue (ASC 606) compared to the prior fiscal year.
- PTC THERAPEUTICS, INC. reported Net Income of $682.64 million for fiscal year 2025.
- PTC THERAPEUTICS, INC. showed an increase of +287.9% in Net Income compared to the prior fiscal year.
- PTC THERAPEUTICS, INC. reported Diluted EPS of $7.78 per share for fiscal year 2025.
- PTC THERAPEUTICS, INC. showed an increase of +264.5% in Diluted EPS compared to the prior fiscal year.
- PTC THERAPEUTICS, INC. reported Total Assets of $2.90 billion for fiscal year 2025.
- PTC THERAPEUTICS, INC. showed an increase of +70.0% in Total Assets compared to the prior fiscal year.
- PTC THERAPEUTICS, INC. reported Cash and Equivalents of $984.65 million for fiscal year 2025.
- PTC THERAPEUTICS, INC. showed an increase of +26.3% in Cash and Equivalents compared to the prior fiscal year.
- PTC THERAPEUTICS, INC. reported Long-Term Debt of $285.41 million for fiscal year 2024.
- PTC THERAPEUTICS, INC. showed an increase of +0.4% in Long-Term Debt compared to the prior fiscal year.
- PTC THERAPEUTICS, INC. reported Stockholders Equity of -$205.31 million for fiscal year 2025.
- PTC THERAPEUTICS, INC. showed an increase of +81.3% in Stockholders Equity compared to the prior fiscal year.
- PTC THERAPEUTICS, INC. reported R&D Expense of $455.25 million for fiscal year 2025.
- PTC THERAPEUTICS, INC. showed a decrease of -14.8% in R&D Expense compared to the prior fiscal year.
- PTC THERAPEUTICS, INC. reported Operating Income of $866.93 million for fiscal year 2025.
- PTC THERAPEUTICS, INC. showed an increase of +386.5% in Operating Income compared to the prior fiscal year.
- PTC THERAPEUTICS, INC. reported Shares Outstanding of 81.47 million shares for fiscal year 2025.
- PTC THERAPEUTICS, INC. showed an increase of +4.9% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: